Merck & Co. has doubled down on its partnership with Variational AI, striking a deal worth up to $349 million to collaborate on small molecule candidates against two targets. Variational disclosed a ...
Transforming drug discovery with generative AI Variational AI is using its Enki platform to explore uncharted regions of the chemical space, accelerating the discovery and development of ...
The collaboration operates within a fully transparent 𝐝𝐞𝐬𝐢𝐠𝐧–𝐦𝐚𝐤𝐞–𝐭𝐞𝐬𝐭–𝐚𝐧𝐚𝐥𝐲𝐳𝐞 (𝐃𝐌𝐓𝐀) framework that integrates AI-driven molecular design, rapid compound synthesis, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results